10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2020 | |||
CONSOLIDATED STATEMENTS OF EARNINGS | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 10, 2021) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Revenues | $ 42,518 | 26,145 | 22,561 |
| Cost of products sold | 11,773 [1] | 8,078 | 6,467 |
| Marketing, selling and administrative | 7,661 | 4,871 | 4,551 |
| Research and development | 11,143 | 6,148 | 6,332 |
| MyoKardia Asset Acquisition IPRD Charge | 11,438 | 0 | 0 |
| Amortization of Acquired Intangible Assets | 9,688 | 1,135 | 97 |
| Other (income)/expense, net | (2,314) | 938 | (854) |
| Total Expenses | 49,389 | 21,170 | 16,593 |
| (Loss)/Earnings Before Income Taxes | (6,871) | 4,975 | 5,968 |
| Provision for Income Taxes | 2,124 | 1,515 | 1,021 |
| Net (Loss)/Earnings | (8,995) | 3,460 | 4,947 |
| Noncontrolling Interest | 20 | 21 | 27 |
| Net (Loss)/Earnings Attributable to BMS | (9,015) | 3,439 | 4,920 |
| Basic Earnings Per Common Share Attributable to BMS | (3.99) | 2.02 | 3.01 |
| Diluted Earnings per Common Share Attributable to BMS | (3.99) | 2.01 | 3.01 |
| Principal Transaction Revenue, Description of Reporting Category | |||
| Net product sales | |||
| Revenues | 41,321 | 25,174 | 21,581 |
| Alliance and other revenues | |||
| Revenues | 1,197 | 971 | 980 |
| [1] Excludes amortization of acquired intangible assets. | |||
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2020 | |||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 10, 2021) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Net (Loss)/Earnings | $ (8,995) | 3,460 | 4,947 |
| Other Comprehensive Income (Loss), net of taxes and reclassifications to earnings [Abstract] | |||
| Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax | (256) | (32) | 70 |
| Pension and postretirement benefits | (75) | 1,203 | 53 |
| Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax | 5 | 36 | (25) |
| Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax | 7 | 35 | (254) |
| Other Comprehensive Income (Loss), Net of Tax | (319) | 1,242 | (156) |
| Comprehensive (Loss)/Income | (9,314) | 4,702 | 4,791 |
| Comprehensive (Loss)/Income Attributable to BMS | (9,334) | 4,681 | 4,764 |
| Noncontrolling Interest | 20 | 21 | 27 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2020 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 10, 2021) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Cash Flows From Operating Activities: | |||
| Net (Loss)/Earnings | $ (8,995) | 3,460 | 4,947 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | |||
| Depreciation and amortization, net | 10,380 | 1,746 | 637 |
| Deferred income taxes | 983 | (924) | 45 |
| Stock-based compensation | 779 | 441 | 221 |
| Impairment charges | 1,203 | 199 | 126 |
| Pension settlements and amortization | 43 | 1,688 | 186 |
| Divestiture gains and royalties | (699) | (1,855) | (992) |
| MyoKardia Asset Acquisition IPRD Charge | 11,438 | 0 | 0 |
| Asset acquisition charges | 1,099 | 63 | 1,211 |
| Gain (Loss) on Investments, Excluding Other than Temporary Impairments | 1,228 | 275 | (513) |
| Equity investment (gains)/losses | (1,228) | (275) | 513 |
| Contingent consideration fair value adjustments | (1,757) | 523 | 0 |
| Other adjustments | (177) | (26) | (45) |
| Changes in operating assets and liabilities: | |||
| Receivables | (646) | 752 | (429) |
| Inventories | 2,672 | 463 | (216) |
| Accounts payable | 188 | 229 | (59) |
| Income taxes payable | (2,305) | 907 | 203 |
| Other | 1,074 | 819 | 718 |
| Net Cash Provided by Operating Activities | 14,052 | 8,210 | 7,066 |
| Cash Flows From Investing Activities: | |||
| Sale and maturities of marketable securities | 6,280 | 3,809 | 2,379 |
| Purchase of marketable securities | (4,172) | (3,961) | (2,305) |
| Capital expenditures | (753) | (836) | (951) |
| Divestiture and other proceeds | 870 | 15,852 | 1,249 |
| Acquisition and other payments, net of cash acquired | (13,084) | (24,777) | (2,372) |
| Net Cash Used in Investing Activities | (10,859) | (9,913) | (2,000) |
| Cash Flows From Financing Activities: | |||
| Short-term borrowings, net | (267) | 131 | (543) |
| Issuance of long-term debt | 6,945 | 26,778 | 0 |
| Repayment of long-term debt | (2,750) | (9,256) | (5) |
| Repurchase of common stock | (1,546) | (7,300) | (320) |
| Dividends | (4,075) | (2,679) | (2,613) |
| Other | 542 | (53) | (54) |
| Net Cash (Used in)/Provided by Financing Activities | (1,151) | 7,621 | (3,535) |
| Effect of Exchange Rate on Cash, Cash Equivalents and Restricted Cash | 111 | (9) | (41) |
| Increase in Cash, Cash Equivalents and Restricted Cash | 2,153 | 5,909 | 1,490 |
| Cash, Cash Equivalents and Restricted Cash | 14,973 | 12,820 | 6,911 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2020 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2020 10-K (Filed: Feb 10, 2021) | ||
| (In Millions) | ||
| As of | As of | |
| Dec 31, 2020 | Dec 31, 2019 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 14,546 | 12,346 |
| Marketable debt securities, current | 1,285 | 3,047 |
| Receivables | 8,501 | 7,685 |
| Inventories | 2,074 | 4,293 |
| Other current assets | 3,786 | 1,983 |
| Total Current Assets | 30,192 | 29,354 |
| Property, plant and equipment | 5,886 | 6,252 |
| Goodwill | 20,547 | 22,488 |
| Other intangible assets | 53,243 | 63,969 |
| Deferred Tax Assets, Net of Valuation Allowance, Noncurrent | 1,161 | 510 |
| Marketable debt securities, noncurrent | 433 | 767 |
| Other Assets, Noncurrent | 7,019 | 6,604 |
| Total Assets | 118,481 | 129,944 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term debt obligations | 2,340 | 3,346 |
| Accounts payable | 2,713 | 2,445 |
| Other current liabilities | 14,027 | 12,513 |
| Total Current Liabilities | 19,080 | 18,304 |
| Deferred Income Tax Liabilities, Net | 5,407 | 6,454 |
| Long-term debt | 48,336 | 43,387 |
| Other Liabilities, Noncurrent | 7,776 | 10,101 |
| Total Liabilities | 80,599 | 78,246 |
| Commitments and contingencies | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019 | 292 | 292 |
| Capital in excess of par value of stock | 44,325 | 43,709 |
| Accumulated other comprehensive loss | (1,839) | (1,520) |
| Retained earnings | 21,281 | 34,474 |
| Less cost of treasury stock - 679 million common shares in 2020 and 672 million common shares in 2019 | (26,237) | (25,357) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 37,822 | 51,598 |
| Noncontrolling interest | 60 | 100 |
| Total Equity | 37,882 | 51,698 |
| Total Liabilities and Equity | 118,481 | 129,944 |
| Preferred Stock, Shares Outstanding | 0 | 0 |
| Preferred Stock, Par or Stated Value Per Share | 1 | 1 |
| Preferred Stock, Shares Authorized | 10 | 10 |
| Preferred Stock, Shares Issued | 0 | 0 |
| Preferred Stock, Liquidation Preference Per Share | 50 | 50 |
| Common Stock, Par or Stated Value Per Share | 0 | 0 |
| Common Stock, Shares Authorized | 4,500 | 4,500 |
| Common Stock, Shares Issued | 2,900 | 2,900 |
| Treasury Stock, Shares | 679 | 672 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |